Tonix Q2 2026: TONMYA net sales $11M (+197% QoQ), net loss $40.6M

Tonix Pharmaceuticals Holding Corp.

TONMYA net sales ~$11M, up 197% QoQ; total net product revenue $13.5M vs $2.0M year ago.
Net loss $40.6M ($2.44/share) vs $28.3M ($3.86/share) in Q2 2025; cash $176.2M at June 30.
First patient enrolled in Phase 2 HORIZON study of TNX-102 SL for MDD; ~360 patients planned.
TNX-4800 Phase 2 Lyme prevention study on track to start Q1 2027 pending FDA agreement.
Sales force to expand to ~150 reps by September; payer coverage ~136M lives (43% U.S.).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.